Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
Nephrology Dialysis Transplantation · 31.01.2024 · 39 (2) · 328-340
DOI: 10.1093/ndt/gfad175 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.08.2023. Verfasst von Fernando Caravaca-Fontán und 53 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain. Hauptthemen laut MEDLINE: Kidney Diseases, Glomerulonephritis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Spanish Young Nephrologists Platform, Fernando Caravaca-Fontán, University of Cambridge.
Abstract (Originalsprache)
Background
The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear.
Methods
This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation.
Results
Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin–angiotensin system blockers were included. Proteinuria from baseline changed by –35%, –41%, –45% and –48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by –6%, –3%, –8% and –10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30–0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: –3.7 versus –5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good.
Conclusions
The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
- Department of Nephrology and Transplantation, Queen Elizabeth University Hospital, Glasgow, UK.
- Department of Nephrology, Complejo Hospitalario de Toledo, Toledo, Spain.
- Department of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
- Department of Nephrology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Spain.
ORCID-Profile: Fernando Caravaca-Fontán, Kate Stevens, Ana Huerta, Marco Montomoli, Amir Shabaka, Marios Papasotiriou, Saúl Pampa-Saico, José Luis Pérez Canga, Blanca Tarragón, Luis F Quintana, Colin Geddes, Manuel Praga
Förderung
- Spanish Young Nephrologists Platform
- Fernando Caravaca-Fontán
- University of Cambridge
- Department of Medicine
- FWF
Zitieren
APA
Caravaca-Fontán, F., Stevens, K., Padrón, M., Huerta, A., Montomoli, M., Villa, J., González, F., Vega, C., López Mendoza, M., Fernández, L., Shabaka, A., Rodríguez-Moreno, A., Martín-Gómez, A., Labrador, P. J., Molina Andújar, A., Prados Soler, M. C., Martín-Penagos, L., Yerovi, E., Medina Zahonero, L., …, & Praga, M. (2024). Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrology Dialysis Transplantation, 39(2), 328-340. https://doi.org/10.1093/ndt/gfad175
Vancouver
Caravaca-Fontán F, Stevens K, Padrón M, Huerta A, Montomoli M, Villa J, et al. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrology Dialysis Transplantation. 2024;39(2):328-340. doi:10.1093/ndt/gfad175
BibTeX
@article{CaravacaFontn2024,
author = {Caravaca-Fontán, Fernando and Stevens, Kate and Padrón, Maite and Huerta, Ana and Montomoli, Marco and Villa, Juan and González, Fayna and Vega, Cristina and López Mendoza, Manuel and Fernández, Loreto and Shabaka, Amir and Rodríguez-Moreno, Antolina and Martín-Gómez, Adoración and Labrador, Pedro J and Molina Andújar, Alicia and Prados Soler, M Carmen and Martín-Penagos, Luis and Yerovi, Estefanía and Medina Zahonero, Laura and De La Flor, José Carlos and Mon, Carmen and Ibernon, Meritxell and Rodríguez Gómez, Astrid and Miquel, Rosa and Sierra, Milagros and Mascarós, Victoria and Luzardo, Leonella and Papasotiriou, Marios and Arroyo, David and Verdalles, Úrsula and Martínez-Miguel, Patricia and Ramírez-Guerrero, Gonzalo and Pampa-Saico, Saúl and Moral Berrio, Esperanza and Canga, José Luis Pérez and Tarragón, Blanca and Fraile Gómez, Pilar and Regidor, Dabaiba and Relea, Javier and Xipell, Marc and Andrades Gómez, Cristina and Navarro, Maruja and Álvarez, Álvaro and Rivas, Begoña and Quintana, Luis F and Gutiérrez, Eduardo and Pérez-Valdivia, Miguel Ángel and Odler, Balazs and Kronbichler, Andreas and Geddes, Colin and Anders, Hans-Joachim and Floege, Jürgen and Fernández-Juárez, Gema and Praga, Manuel},
title = {Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
volume = {39},
number = {2},
pages = {328--340},
doi = {10.1093/ndt/gfad175}
}
EUVIMED